title: Cocaine drives aversive conditioning via delayed activation of dopamine-responsive habenular and midbrain pathways.
abstract: Many strong rewards, including abused drugs, also produce aversive effects that are poorly understood. For example, cocaine can produce aversive conditioning after its rewarding effects have dissipated, consistent with opponent process theory, but the neural mechanisms involved are not well known. Using electrophysiological recordings in awake rats, we found that some neurons in the lateral habenula (LHb), where activation produces aversive conditioning, exhibited biphasic responses to single doses of intravenous cocaine, with an initial inhibition followed by delayed excitation paralleling cocaine's shift from rewarding to aversive. Recordings in LHb slice preparations revealed similar cocaine-induced biphasic responses and further demonstrated that biphasic responses were mimicked by dopamine, that the inhibitory phase depended on dopamine D2-like receptors, and that the delayed excitation persisted after drug washout for prolonged durations consistent with findings in vivo. c-Fos experiments further showed that cocaine-activated LHb neurons preferentially projected to and activated neurons in the rostromedial tegmental nucleus (RMTg), a recently identified target of LHb axons that is activated by negative motivational stimuli and inhibits dopamine neurons. Finally, pharmacological excitation of the RMTg produced conditioned place aversion, whereas cocaine-induced avoidance behaviors in a runway operant paradigm were abolished by lesions of LHb efferents, lesions of the RMTg, or by optogenetic inactivation of the RMTg selectively during the period when LHb neurons are activated by cocaine. Together, these results indicate that LHb/RMTg pathways contribute critically to cocaine-induced avoidance behaviors, while also participating in reciprocally inhibitory interactions with dopamine neurons.
authors.affiliation: Behavioral Neuroscience Research Branch and Electrophysiology Research Section, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Baltimore, Maryland 21224, USA. jhou@musc.edu
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Jhou
authors.forename: Cameron H
authors.initials: CH
authors.lastname: Good
authors.forename: Courtney S
authors.initials: CS
authors.lastname: Rowley
authors.forename: Sheng-Ping
authors.initials: SP
authors.lastname: Xu
authors.forename: Huikun
authors.initials: H
authors.lastname: Wang
authors.forename: Nathan W
authors.initials: NW
authors.lastname: Burnham
authors.forename: Alexander F
authors.initials: AF
authors.lastname: Hoffman
authors.forename: Carl R
authors.initials: CR
authors.lastname: Lupica
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikemoto
mesh_terms: D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects* / Q000502:physiology; D003042:Cocaine / Q000008:administration & dosage*; D003216:Conditioning, Operant / Q000187:drug effects* / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D019262:Habenula / Q000187:drug effects* / Q000502:physiology; D007275:Injections, Intravenous; D008297:Male; D008636:Mesencephalon / Q000187:drug effects* / Q000502:physiology; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar
chemical_list: D003042:Cocaine; D004298:Dopamine